Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Beltropolis Boy who wrote (1172)	11/2/1999 7:25:00 PM
From: Mark Bong	Respond to of 1686

Bad News and Good News Good News: Jim Vincent says "In our research to date, we have seen early evidence of biological efficacy and activity across several indications. Based on our clinical experience so far, we believe that if we can safely block this pathway, the drug may have significant therapeutic benefit in important diseases. However, there is work that must be done before we can return to the clinic." Bad News: Jim Vincent says "Biogen, Inc. today announced that it has halted the ongoing clinical trials of its anti-CD40 ligand monoclonal antibody until the Company has completed its review of issues relating to adverse events. The Company said it had taken this measure in the interests of patient safety and that one additional thrombo-embolic event had taken place since October 21. Read the whole press release here. biz.yahoo.com